

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
<b>Anreas M. ZEIHHER et al.</b>	)	
	)	Group Art Unit: <b>Not Yet Assigned</b>
Application No.: <b>Not Yet Assigned</b>	)	
	)	Examiner: <b>Not Yet Assigned</b>
Filed: <b>May 16, 2005</b>	)	
	)	
National Stage of International Application No.	)	
<b>PCT/EP2003/012531</b> under 35 U.S.C. 371,	)	
for <b>SCD40L AND PLACENTAL GROWTH</b>	)	
<b>FACTOR (PLGF) USED AS A</b>	)	
<b>BIOCHEMICAL MARKER COMBINATION IN</b>	)	
<b>CARDIOVASCULAR DISEASES</b>	)	

**MAIL STOP PCT**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08 and cited in the international search report. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in a PTO international application.

Also enclosed is an English-language international search report from the Patent Office in the PCT international application, from which this national phase U.S. application is derived, citing these documents and setting forth the relevance thereof.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: May 18, 2005

By: 

Ernest F. Chapman  
Reg. No. 25,961

Enclosures  
EFC/FPD/sci

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	May 16, 2005
				First Named Inventor	Anreas M. ZEIHNER et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	05552.1459

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		WO 03/040691 A2	05-15-2003	SCHOENBECK et al.		
		WO 98/20155	05-14-1998	CROW et al.		
		WO 02/056015 A1	07-18-2002	CONOVER et al.		
		WO 01/56593 A2	08-09-2001	CARMELIET et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		SCHÖNBECK, U. et al., "Soluble CD40L and Cardiovascular Risk in Women," CIRCULATION, Vol. 104, No. 19, pp. 2266-2268, (November 6, 2001).	
		PENG, D. Q. et al., "Elevated Soluble CD40 Ligand is Related to the Endothelial Adhesion Molecules in Patients with Acute Coronary Syndrome," Clinica Chimica Acta, Vol. 319, No. 1, pp. 19-26, (May 7, 2002).	
		YAN, J. et al., "Clinical Implications of Increased Expression of CD40L in Patients with Acute Coronary Syndromes," Chinese Medical Journal, Vol. 115, No. 4, pp. 491-493, (April 2002).	
		AUKRUST, P. et al., "Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable Angina: Possible Reflection of T Lymphocyte and Platelet Involvement in the Pathogenesis of Acute Coronary Syndromes," CIRCULATION, Vol. 100, No. 6, pp. 614-620, (August 10, 1999).	
		HEESCHEN, C. et al., "CD40 Ligand Serum Levels Independently Predicts Outcome and Effect of Anti-Platelet Therapy in Patients with Unstable Angina," CIRCULATION, Vol. 106, No. 19 Supplement, p. II.402, XP008028499, (November 5, 2002).	
		GARLICH, C. D. et al., "Patients with Acute Coronary Syndrome Express Enhanced CD40 Ligand/CD154 on Platelets," HEART, Vol. 86, No. 6, pp. 649-655, (December 2001).	
		BAYES-GENIS, A. et al., "Identification of Pregnancy-Associated Plasma Protein A (PAPP-A) as New Marker of Acute Coronary Syndromes," Journal of The American College of Cardiology, Vol. 37, No. 2 Supplement A, p. 301A, XP008028486, (February 2001).	
		VARO, N. et al., "Soluble CD40L: Risk Prediction After Acute Coronary Syndromes," CIRCULATION, Vol. 108, No. 9, pp. 1049-1052, (September 2, 2003).	
		BAYES-GENIS, A. et al., "Pregnancy-Associated Plasma Protein A As a Marker of Acute Coronary Syndromes," New England Journal of Medicine, Vol. 345, No. 14, pp. 1022-1029, (October 4, 2001).	
		KHOSRAVI, J. et al., "Pregnancy Associated Plasma Protein-A: Ultrasensitive Immunoassay and Determination in Coronary Heart Disease," Clinical Biochemistry, Vol. 35, No. 7, pp. 531-538, (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	May 16, 2005
				First Named Inventor	Anreas M. ZEIHHER et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05552.1459

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>7</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>8</sup> (if known)			

**Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>12</sup>
		Country Code <sup>9</sup> Number <sup>10</sup> Kind Code <sup>11</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		DENKTAS, A. E. et al., "Pregnancy Associated Plasma Protein-A Levels Are Elevated in Patients With Unstable Angina," European Heart Journal, The European Society of Cardiology, XX, Vo. 23, No. ABSTR SUPPL, p. 466, XP008028493, (August 31, 2002).	
		HAJEK, P. et al., "Pregnancy-Associated Plasma Protein a (PAPP-a) in Determination of Unstable Coronary Plaque," European Heart Journal, Vol. 23, No. Abstract Supplement, p. 293, XP008028492, (2002).	
		FUTTERMAN, L. G. et al., "Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A," American Journal of Critical Care, Vol. 11, No. 2, pp. 168-172, (March 2002).	
		MAGLIONE, D. et al., "Recombinant Production of PIGF-1 and Its Activity in Animal Models," IL FARMACO, Vol. 55, pp. 165-167, (2000).	
		LUTTUN, A. et al., "Revascularization of Ischemic Tissues by PIGF Treatment, and Inhibition of Tumor angiogenesis, Arthritis and Atherosclerosis by Anti-Flt1," Nature Medicine, Vol. 8, No. 8, pp. 831-840, (August 2002).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.